JAJessica L. Ables

Jessica L. Ables

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jessica L. Ables has a total of 184 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A randomized, controlled experimental medicine study of the novel Kv7 channel opener azetukalner in individuals with major depressive disorder and anhedonia

    by Rachel Fremont, Philipp T. Neukam, Usha S. Govindarajulu, Jessica L. Ables, Sara Hameed, Marcella Corwin, Mackenzie B. Hargrove, Helena L. Chang, Sarah Boukezzi, Chris A. Kelly, et al.

    Major Depressive Disorder (MDD) is a common and debilitating disease. Kv7 potassium channels are relevant to reward processing and represent a novel target for depression and anhedonia. Azetukalner is a positive allosteric modulator of Kv7 channels. This phase II, randomized, double-blind, placebo-controlled trial assessed changes in brain reward function, clinical outcomes, and safety following treatment with azetukalner or placebo in individuals with MDD and anhedonia. The study included 60 participants with MDD and anhedonia in a current major depressive episode. Participants were randomized 1:1 to receive azetukalner (20 mg orally once daily with food) or placebo for 8 weeks. The primary endpoint was change in bilateral ventral striatum (VS) activity assessed by functional MRI (fMRI) during a reward task from baseline to week 8. Secondary endpoints included changes in depression severity and anhedonia measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) and Snaith-Hamilton Pleasure Scale (SHAPS). Of 60 participants, 29 were randomized to azetukalner and 31 to placebo. There was no significant difference in VS response to reward anticipation between groups. Compared to placebo, azetukalner was associated with numerical benefit on the MADRS and SHAPS that did not reach statistical significance. Most exploratory endpoints numerically favored azetukalner over placebo. Discontinuation rates due to adverse events were low and did not differ across groups. Despite not meeting the primary neuroimaging endpoint, secondary and exploratory outcomes suggested potential improvement in depressive symptoms and anhedonia. Trial Registration: Clinicaltrials.gov ID NCT04827901.

  • Open Access

    Cholinergic interneurons in the nucleus accumbens regulate the initiation of natural reward approach

    by Samantha O. Brown, Romain Durand-De Cuttoli, Mariam A. Mahboob, Eftychia Markopoulou, Inés Ibañez-Tallon, Jessica L. Ables

    Summary: Despite their established role in motivated behavior, how nucleus accumbens (NAc) cholinergic interneurons (CINs) contribute to natural reward seeking remains unclear. Here, we report that NAc CINs are key modulators of the approach phase of reward pursuit. Using in vivo fiber photometry in Chat-ires-Cre mice, we show that NAc CINs are robustly activated during the approach towards several salient stimuli including food, a social target, and a familiar object. We also provide evidence that this activation is potentially driven by olfactory cues. Disrupting NAc CIN function via targeted expression of a membrane-tethered toxin results in a delayed approach towards both food and a social target, but no alterations in object investigation, general locomotion or anxiety-related measures. Together, these findings identify NAc CINs as regulators of the initiation of natural reward approach and suggest that they link sensory information with onset of motivated action.

  • Open Access

    A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety

    by James Murrough, Rachel Fremont, Philipp Neukam, Usha Govindarajulu, Jessica Ables, Sara Hameed, Marcella Corwin, Mackenzie Hargrove, Helena Chang, Sarah Boukezzi, et al.

    Major Depressive Disorder (MDD) is a common and debilitating disease. Kv7 potassium channels are relevant to reward processing and represent a novel target for depression and anhedonia. Azetukalner is a positive allosteric modulator of Kv7. This phase II, randomized, double-blind, placebo-controlled trial assessed changes in brain reward function, clinical outcomes, and safety following treatment with azetukalner or placebo in individuals with MDD and anhedonia. The study included 60 participants with MDD and anhedonia in a current major depressive episode. Participants were randomized 1:1 to receive azetukalner (20 mg orally once daily with food) or placebo for 8 weeks. The primary endpoint was change in bilateral ventral striatum (VS) activity assessed by fMRI during a reward task from baseline to week 8. Secondary endpoints included changes in depression severity and anhedonia measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) and Snaith-Hamilton Pleasure Scale (SHAPS). Of 60 participants, 29 were randomized to azetukalner and 31 to placebo. There was no significant difference in VS response to reward anticipation between groups. Compared to placebo, azetukalner was associated with numerical benefit on the MADRS and SHAPS that did not reach statistical significance. Additional exploratory endpoints also favored azetukalner over placebo. Discontinuation rates due to adverse events were low and did not differ across groups. Despite not meeting the primary neuroimaging endpoint,secondary and exploratory outcomes suggested potential improvement in depressive and anhedonia symptoms, consistent with recent studies. Trial Registration: Clinicaltrials.gov ID NCT04827901


  • Open Access

    Neuroeconomically dissociable forms of mental accounting are altered in a mouse model of diabetes

    by Chinonso A. Nwakama, Romain Durand-De Cuttoli, Zainab M. Oketokoun, Samantha O. Brown, Jillian E. Haller, Adriana Méndez, Mohammad Jodeiri Farshbaf, Y. Zoe Cho, Sanjana Ahmed, Sophia Leng, et al.

    Those with diabetes mellitus are at high-risk of developing psychiatric disorders, especially mood disorders, yet the link between hyperglycemia and altered motivation has not been thoroughly explored. Here, we characterized value-based decision-making behavior of a streptozocin-induced diabetic mouse model on Restaurant Row, a naturalistic neuroeconomic foraging paradigm capable of behaviorally capturing multiple decision systems known to depend on dissociable neural circuits. Mice made self-paced choices on a daily limited time-budget, accepting or rejecting reward offers based on cost (delays cued by tone pitch) and subjective value (flavors), in a closed-economy system tested across months. We found streptozocin-treated mice disproportionately undervalued less-preferred flavors and inverted their meal-consumption patterns shifted toward a more costly strategy overprioritizing high-value rewards. These foraging behaviors were driven by impairments in multiple decision-making processes, including the ability to deliberate when engaged in conflict and cache the value of the passage of time as sunk costs. Surprisingly, diabetes-induced changes in motivation depended not only on the type of choice being made, but also on the salience of reward-scarcity in the environment. These findings suggest that complex relationships between metabolic dysfunction and dissociable valuation algorithms underlying unique cognitive heuristics and sensitivity to opportunity costs can disrupt distinct computational processes leading to comorbid psychiatric vulnerabilities.


  • Open Access

    STZ-induced hyperglycemia differentially influences mitochondrial distribution and morphology in the habenulointerpeduncular circuit

    by Mohammad Jodeiri Farshbaf, Taelor A. Matos, Kristi Niblo, Yacoub Alokam, Jessica L. Ables

    Introduction: Diabetes is a metabolic disorder of glucose homeostasis that is a significant risk factor for neurodegenerative diseases, such as Alzheimer’s disease, as well as mood disorders, which often precede neurodegenerative conditions. We examined the medial habenulainterpeduncular nucleus (MHb-IPN), as this circuit plays crucial roles in mood regulation, has been linked to the development of diabetes after smoking, and is rich in cholinergic neurons, which are affected in other brain areas in Alzheimer’s disease.Methods: This study aimed to investigate the impact of streptozotocin (STZ)-induced hyperglycemia, a type 1 diabetes model, on mitochondrial and lipid homeostasis in 4% paraformaldehyde-fixed sections from the MHb and IPN of C57BL/6 J male mice, using a recently developed automated pipeline for mitochondrial analysis in confocal images. We examined different time points after STZ-induced diabetes onset to determine how the brain responded to chronic hyperglycemia, with the limitation that mitochondria and lipids were not examined with respect to cell type or intracellular location.Results: Mitochondrial distribution and morphology differentially responded to hyperglycemia depending on time and brain area. Six weeks after STZ treatment, mitochondria in the ventral MHb and dorsal IPN increased in number and exhibited altered morphology, but no changes were observed in the lateral habenula (LHb) or ventral IPN. Strikingly, mitochondrial numbers returned to normal dynamics at 12 weeks. Both blood glucose level and glycated hemoglobin (HbA1C) correlated with mitochondrial dynamics in ventral MHb, whereas only HbA1C correlated in the IPN. We also examined lipid homeostasis using BODIPY staining for neutral lipids in this model given that diabetes is associated with disrupted lipid homeostasis. BODIPY staining intensity was unchanged in the vMHb of STZ-treated mice but increased in the IPN and VTA and decreased in the LHb at 12 weeks. Interestingly, areas that demonstrated changes in mitochondria had little change in lipid staining and vice versa.Discussion: This study is the first to describe the specific impacts of diabetes on mitochondria in the MHb-IPN circuit and suggests that the cholinergic MHb is uniquely sensitive to diabetesinduced hyperglycemia. Further studies are needed to understand the functional and behavioral implications of these findings.


  • A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers

    by Jessica L Ables, Leah Israel, Olivia Wood, Usha Govindarajulu, Rachel T Fremont, Ronjon Banerjee, Hongtao Liu, Jeremy Cohen, Peng Wang, Kunal Kumar, et al.

    Background: Harmine is a component of the hallucinogenic brew, Ayahuasca, which also contains the psychoactive compound, N, N-dimethyltryptamine. Whether pharmaceutical-grade harmine hydrochloride (HCl) has psychoactive effects, the doses at which these might occur, and the dose-response relationship to side effects and safety in humans are unknown. Methods: We conducted a Phase 1, open-label single ascending dose trial in healthy adults with normal body mass index and no prior psychiatric illness. The primary goal was to determine the maximum tolerated dose (MTD) of oral pharmaceutical-grade harmine HCl and to characterize safety and tolerability. A secondary goal was to ascertain whether any oral dose has psychoactive effects. Results: Thirty-four adult participants, aged 18–55 years, were screened for study eligibility. Twenty-five participants met eligibility criteria and were randomized to a single dose of 100, 200, 300, or 500 mg of harmine HCl, respectively, using a continuous reassessment method. The most common adverse events (AEs) observed were gastrointestinal and/or neurological, dose-related, and of mild to moderate severity. The MTD was determined to be between 100 and 200 mg and is weight-based, with 90% of those participants receiving >2.7 mg/kg experiencing a dose-limiting toxicity. No serious AEs of harmine HCl were identified. Conclusions: Harmine HCl can be orally administered to healthy participants in doses 2.7 mg/kg are associated with vomiting, drowsiness, and limited psychoactivity. This study is the first to systematically characterize the psychoactive effects of pharmaceutical quality harmine in healthy participants.


  • Open Access

    Diabetes alters neuroeconomically dissociable forms of mental accounting

    by Chinonso A. Nwakama, Romain Durand-De Cuttoli, Zainab M. Oketokoun, Samantha O. Brown, Jillian E. Haller, Adriana Méndez, Mohammad Jodeiri Farshbaf, Y. Zoe Cho, Sanjana Ahmed, Sophia Leng, et al.

    Those with diabetes mellitus are at high-risk of developing psychiatric disorders, yet the link between hyperglycemia and alterations in motivated behavior has not been explored in detail. We characterized value-based decision-making behavior of a streptozocin-induced diabetic mouse model on a naturalistic neuroeconomic foraging paradigm called Restaurant Row. Mice made self-paced choices while on a limited time-budget accepting or rejecting reward offers as a function of cost (delays cued by tone-pitch) and subjective value (flavors), tested daily in a closed-economy system across months. We found streptozocin-treated mice disproportionately undervalued less-preferred flavors and inverted their meal-consumption patterns shifted toward a more costly strategy that overprioritized high-value rewards. We discovered these foraging behaviors were driven by impairments in multiple decision-making systems, including the ability to deliberate when engaged in conflict and cache the value of the passage of time in the form of sunk costs. Surprisingly, diabetes-induced changes in behavior depended not only on the type of choice being made but also the salience of reward-scarcity in the environment. These findings suggest complex relationships between glycemic regulation and dissociable valuation algorithms underlying unique cognitive heuristics and sensitivity to opportunity costs can disrupt fundamentally distinct computational processes and could give rise to psychiatric vulnerabilities.


  • 494. Interpeduncular NOS1 Mediates Oxycodone Reward Tolerance

    by Kristi Niblo, Mohammad Jodeiri Farshbaf, Zainab Oketokoun, Clementine Fillinger, Gabrielle Chavez, Purva Bali, Mary Heyer, Paul Kenny, Jessica Ables

  • Open Access

    Hedgehog-interacting protein acts in the habenula to regulate nicotine intake

    by Stephanie P. B. Caligiuri, William M. Howe, Lauren Wills, Alexander C. W. Smith, Ye Lei, Purva Bali, Mary P. Heyer, Janna K. Moen, Jessica L. Ables, Karim S. Elayouby, et al.

    Hedgehog-interacting protein (HHIP) sequesters Hedgehog ligands to repress Smoothened (SMO)-mediated recruitment of the GLI family of transcription factors. Allelic variation in HHIP confers risk of chronic obstructive pulmonary disease and other smoking-related lung diseases, but underlying mechanisms are unclear. Using single-cell and cell-type-specific translational profiling, we show that HHIP expression is highly enriched in medial habenula (MHb) neurons, particularly MHb cholinergic neurons that regulate aversive behavioral responses to nicotine. HHIP deficiency dysregulated the expression of genes involved in cholinergic signaling in the MHb and disrupted the function of nicotinic acetylcholine receptors (nAChRs) through a PTCH-1/cholesterol-dependent mechanism. Further, CRISPR/Cas9-mediated genomic cleavage of the Hhip gene in MHb neurons enhanced the motivational properties of nicotine in mice. These findings suggest that HHIP influences vulnerability to smoking-related lung diseases in part by regulating the actions of nicotine on habenular aversion circuits.


  • Retrograde inhibition by a specific subset of interpeduncular α5 nicotinic neurons regulates nicotine preference

    by Jessica L. Ables, Andreas Görlich, Beatriz Antolin-Fontes, Cuidong Wang, Sylvia M. Lipford, Michael H. Riad, Jing Ren, Fei Hu, Minmin Luo, Paul J. Kenny, et al.

    Significance: The CHRNA5-A3-B4 gene cluster, which encodes the α5, α3, and β4 nicotinic acetylcholine receptor subunits, has been genetically associated with high risk of developing nicotine dependence. Here we show that a specific α5 nicotinic receptor population in the midbrain interpeduncular nucleus (IPN) responds to chronic nicotine by increasing the expression of genes that regulate feedback inhibition of the medial habenula, the major source of input to the IPN. Inhibiting neurotransmitter release from this population of α5 + neurons or reducing expression of one of these genes, Nos1 , blocks the rewarding effects of nicotine. Our data identify molecular mechanisms that may explain the genetic link between CHRNA5 and smoking predisposition in humans.